NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and nivolumab with radiation therapy (RT) did not improve progression-free survival (PFS) for patients with newly diagnosed MGMT-unmethylated (uMGMT) glioblastoma in comparison to standard RT with temozolomide (TMZ). Accordingly, this trial will not progress to a phase III. These results were recently published in the Journal of Clinical Oncology.
Go to Source
https://medicalxpress.com/rss-feed/